Quarterly figures on 01.02.2023...
Figures interest and yield... today everything there
Today there was the FED interest rate decision and the FED increases, as expected by 25 basis points. In addition, the Fed says that further increases are necessary, but the pressure is taken out a bit, so you could count on 2 more increases until May, then they have reached their 5% and then it could possibly be over. I am curious...but now first of all the quarterly figures from today!
$META
Meta Platforms:
Missed analyst estimates of $2.26 in the fourth quarter with earnings per share of $1.76. Revenue of $32.17 billion above expectations of $31.53 billion. Meta expands buybacks by $40 billion.
$TMUS
T-Mobile US Inc:
fourth-quarter earnings per share of $1.18 beat analyst estimates of $1.07; Ebitda (adjusted) of $6.83 billion exceeded analyst estimates of $6.71 billion; revenue of $20.27 billion below expectations of $20.7 billion; in outlook for 2023, T-Mobile US expects Ebitda (adjusted) of $28.7 billion to $29.2 billion (analyst forecast: $29.3 billion), free cash flow of $13.1 billion to $13.6 billion (forecast: $13.6 billion), and capex of $9.4 billion to $9.7 billion (forecast: $10.3 billion).
$NOVN
Novartis:
Posts Q4 sales of $12.8 billion (analyst forecast: $13 billion), core EBIT of $4.03 billion (forecast: $3.8 billion) and core net income of $3.25 billion (forecast: $3 billion). In the 2023 outlook, sales are expected to grow in the low to mid-single digits; operating income is expected to grow in the mid-single digits. Sandoz spin-off still on track for second-half 2023, but shareholders are still expected to enjoy a higher dividend for the past year. This is to rise to 3.20 Swiss francs from 3.10 francs in 2021.
$NOVO B
Novo Nordisk:
Net income rose to 13.59 billion kroner from 10.89 billion kroner, thanks to strong demand for diabetes and obesity drugs, the company said. It beat the consensus forecast of 13.08 billion kroner by analysts surveyed by FactSet. Sales also exceeded analysts' expectations (47.26 billion kronor), growing 25 percent to 48.09 billion kronor. While revenue from drugs to treat diabetes and obesity rose sharply in some cases, insulin sales fell 12 percent. Novo Nordisk expects 2023 sales growth and operating profit growth in a range of 13 to 19 percent in local currencies. Nominal sales growth is expected to be about 4 percentage points below comparable growth, and reported operating profit growth about 5 percentage points below. Novo Nordisk proposed a final dividend of 8.15 kroner, which would bring the total dividend for 2022 to 12.40 kroner (previous year: 10.40).
#meta
#novonordisk
#novartis
#tmobileus
#inflation
#zinswende
#zinserhöhung
#powell
#fed
#quartalszahlen
#aktien
#boerse
#börse
#dividende
#dividenden
#news
#newsroom
#nachrichten
#investieren
#zinsen
![](https://static.getquin.com/media/activity/mEVsalGQkW/FpNfGfkTdy_F_xQiWsMOI.gif)